Sciclone Pharmaceuticals, Inc. (SCLN) Tops Q3 EPS by 5c, Boosts FY EPS Guidance

Sciclone Pharmaceuticals, Inc. (NASDAQ: SCLN) reported Q3 EPS of $0.17, $0.05 better than the analyst estimate of $0.12. Revenue for the quarter came in at $34.3 million versus the consensus estimate of $34.9 million.

Sciclone Pharmaceuticals, Inc. sees FY2014 EPS of $0.64-$0.68, versus prior guidance of $0.51-$0.57 and the consensus of $0.49. SciClone continues to project revenue of $130 million to $135 million.

For earnings history and earnings-related data on Sciclone Pharmaceuticals, Inc. (SCLN) click here.

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• West Pharma (WST) Tops Q1 EPS by 26c, provides guidance
• STMicroelectronics cuts outlook as slower demand causes Q1 miss